文献速递类风湿关节炎

类风湿关节炎前后乳腺癌风险及激素因素影响

Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.
PubMed 文献 · Ann Rheum Dis · 2020-03-11

基于瑞典全国登记数据,新发类风湿关节炎(RA)女性乳腺癌发病风险降低(HR=0.80, 95%CI 0.68-0.93),且有乳腺癌史的女性RA风险亦降低(OR=0.87, 95%CI 0.79-0.95)。乳腺癌抗激素治疗(他莫昔芬或芳香化酶抑制剂)未增加RA风险。

要点

  • RA女性乳腺癌风险降低,调整乳腺癌风险因素后关联未减弱。
  • 有乳腺癌史的女性RA风险同样降低。
  • 乳腺癌抗激素治疗不增加RA风险。

核心结论

  • RA患者乳腺癌发生率降低在RA诊断前已存在,且不能由激素风险因素解释。
  • 乳腺癌辅助抗激素治疗似乎不增加RA风险。

研究设计与样本

  • 基于瑞典全国登记数据的队列和病例对照设计,纳入2006-2016年新发RA女性,每例RA按年龄、性别和居住地匹配5名普通人群对照。

主要发现

  • RA女性发生乳腺癌的风险降低(HR=0.80, 95%CI 0.68-0.93),调整乳腺癌风险因素后关联未减弱。
  • 有乳腺癌史的女性发生RA的风险降低(OR=0.87, 95%CI 0.79-0.95)。
  • 乳腺癌患者使用他莫昔芬(OR=0.86, 95%CI 0.62-1.20)或芳香化酶抑制剂(OR=0.97, 95%CI 0.69-1.37)者与接受其他治疗者相比,RA风险未增加。

临床怎么用

  • 临床中RA女性乳腺癌风险降低,乳腺癌病史女性RA风险亦降低,抗激素治疗不增加RA风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the risk of incident breast cancer in women with rheumatoid arthritis (RA), and the risk of RA in women with a history of breast cancer, taking antihormonal treatment for breast cancer into account. METHODS: Using nationwide Swedish registers, women with new-onset RA diagnosed in 2006-2016 were identified and analysed using a cohort and a case-control design. Each patient with RA was matched on age, sex and place of residence to five randomly selected subjects from the general population. Through register linkages, we collected information on breast cancer, breast cancer risk factors (reproductive history and hormone replacement therapy) and socio-economy. The relative risk of breast cancer after RA was assessed using Cox regression, and the relative risk of RA in women with a history of breast cancer was assessed using conditional logistic regression. RESULTS: The risk of incident breast cancer in women with RA was reduced and the association was not attenuated by adjustment for breast cancer risk factors (HR=0.80, 95% CI 0.68 to 0.93). The risk of RA in women with a history of breast cancer was similarly reduced (OR=0.87, 95% CI 0.79 to 0.95). Women with breast cancer treated with tamoxifen (OR=0.86, 95% CI 0.62 to 1.20) or aromatase inhibitors (OR=0.97, 95% CI 0.69 to 1.37) did not have an increased risk of RA compared with women with breast cancer treated differently. CONCLUSIONS: The decreased occurrence of breast cancer in patients with RA is present already before RA diagnosis; these reduced risks are not readily explained by hormonal risk factors. Adjuvant antihormonal therapy for breast cancer does not seem to increase RA risk.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Wadström H, Pettersson A, Smedby KE, et al. Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors. Ann Rheum Dis. 2020. PMID: 32161056. doi:10.1136/annrheumdis-2019-216756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。